You are here

  • Home
  • Archive
  • Volume 21, Issue 3
  • Pegylated Liposomal Doxorubicin and Gemcitabine in a Fixed Dose Rate Infusion for the Treatment of Patients With Poor Prognosis of Recurrent Ovarian Cancer: A Phase Ib Study

Article info

Article menu
Download PDFPDF
Ovarian Cancer
Pegylated Liposomal Doxorubicin and Gemcitabine in a Fixed Dose Rate Infusion for the Treatment of Patients With Poor Prognosis of Recurrent Ovarian Cancer: A Phase Ib Study

Authors

  • Guillermo Crespo Department of Medical Oncology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain; PubMed articlesGoogle scholar articles
  • Marta Sierra Laboratory of Medical Oncology, HUCA, Oviedo, Spain;Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Obra Social CajAstur, Oviedo, Spain. PubMed articlesGoogle scholar articles
  • Raquel Losa Laboratory of Medical Oncology, HUCA, Oviedo, Spain;Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Obra Social CajAstur, Oviedo, Spain. PubMed articlesGoogle scholar articles
  • José Pablo Berros Department of Medical Oncology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain; PubMed articlesGoogle scholar articles
  • Noemí Villanueva Department of Medical Oncology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain;Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Obra Social CajAstur, Oviedo, Spain. PubMed articlesGoogle scholar articles
  • Joaquín Fra Department of Medical Oncology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain;Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Obra Social CajAstur, Oviedo, Spain. PubMed articlesGoogle scholar articles
  • Paula J. Fonseca Department of Medical Oncology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain;Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Obra Social CajAstur, Oviedo, Spain. PubMed articlesGoogle scholar articles
  • María Luque Department of Medical Oncology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain;Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Obra Social CajAstur, Oviedo, Spain. PubMed articlesGoogle scholar articles
  • Yolanda Fernández Department of Medical Oncology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain;Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Obra Social CajAstur, Oviedo, Spain. PubMed articlesGoogle scholar articles
  • Pilar Blay Department of Medical Oncology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain;Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Obra Social CajAstur, Oviedo, Spain. PubMed articlesGoogle scholar articles
  • Miguel Sanmamed Department of Medical Oncology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain; PubMed articlesGoogle scholar articles
  • Carolina Muriel Department of Medical Oncology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain; PubMed articlesGoogle scholar articles
  • Emilio Esteban Department of Medical Oncology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain;Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Obra Social CajAstur, Oviedo, Spain. PubMed articlesGoogle scholar articles
  • Ángel J. Lacave Department of Medical Oncology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain;Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Obra Social CajAstur, Oviedo, Spain. PubMed articlesGoogle scholar articles
  1. Address correspondence and reprint requests to Guillermo Crespo, PhD, Hospital Universitario Central de Asturias, C/ Celestino Villamil s/n, Oviedo 33005, Spain. E-mail: gcrespoherrero{at}hotmail.com.

Citation

Crespo G, Sierra M, Losa R, et al
Pegylated Liposomal Doxorubicin and Gemcitabine in a Fixed Dose Rate Infusion for the Treatment of Patients With Poor Prognosis of Recurrent Ovarian Cancer: A Phase Ib Study
International Journal of Gynecologic Cancer 2011;21:478-485.

Publication history

  • Received September 14, 2010
  • First published April 1, 2011.
Online issue publication 
April 01, 2011

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Copyright © 2011 by IGCS and ESGO